摘要
目的研究胸腺肽α1对恩替卡韦治疗HBeAg阳性慢性乙型肝炎疗效的影响。方法将HBeAg阳性慢性乙型肝炎根据治疗方法分为恩替卡韦治疗组(对照组)和恩替卡韦联合胸腺肽α1治疗组(联合组),比较两组患者ALT复常率、AST复常率、HBeAg阴转率、HBeAg血清学率、HBVDNA转阴率和不良反应的差异。结果联合组患者治疗后ALT复常率、AST复常率、HBeAg阴转率、HBeAg血清学率、HBVDNA转阴率均高于对照组,其中在ALT复常率、AST复常率和HBVDNA转阴率的差异具有统计学意义(均P<0.05)。联合组患者头痛、疲劳、眩晕、恶心及其他不良反应发生率低于对照组,但差异均无统计学意义(均P>0.05)。结论胸腺肽α1可增强恩替卡韦治疗HBeAg阳性慢性乙型肝炎疗效,对不良反应物明显影响。
Objective To investigate the influence of thymosin α1 on therapeutic effect of entecavir for chronic hep- atitis B with positive HBeAg. Methods According to the therapy, the patients of chronic hepatitis B with positive HBeAg were assigned to entecavir group （control group） and entecavir plus thymosin α1 group （combined group）. The differences of renormalization rate of ALT and AST, return-to-negative rate of HBeAg, serological rate of HBeAg, re- turn-to-negative rate of HBV DNA, and adverse reaction between two groups were compared. Results For patients in combined group, the renormalization rate of ALT and AST, return-to-negative rate of HBeAg, serological rate of HBeAg, and return-to-negative rate of HBV DNA were higher than those of control group after treatment. The be- tween-group differences of renormalization rate of ALT and AST, and return-to-negative rate of HBV DNA were statistic （all P 〈 0.05）. The incidence of headache, fatigue, dizziness, nausea, and other adverse reactions were lower than those of control group, but no statistic differences （all P 〉 0.05）. Conclusion Thymosin α1 can improve the thera- peutic effect of entecavir for chronic hepatitis B with positive HBeAg and has no significant influence on adverse reac- tion.
出处
《中国当代医药》
2013年第11期40-41,共2页
China Modern Medicine
关键词
慢性乙型肝炎
恩替卡韦
胸腺肽Α1
疗效
Chronic hepatitis B
Entecavir
Thymosin α1
Therapeutic effect
